A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia
Clinical trial NCT05929807 · ENROLLING_BY_INVITATION
Trial details
- NCT number
- NCT05929807
- Sponsor
- Ascendis Pharma Growth Disorders A/S
- Status
- ENROLLING_BY_INVITATION
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-06-21
- Primary completion
- 2039-01-01
- Enrollment
- 140
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.